Acasti Pharma News - ACST

Company Name	Stock Ticker Symbol	Market	Type
Acasti Pharma Inc	ACST	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	-0.04	-1.38%	2.86	09:30:00

Open Price	Low Price	High Price	Close Price	Prev Close
2.86	2.86	2.86		2.90

more quote information »

Recent News

Date	Time	Source	Heading
4/25/2024	8:52	IHNW	FeaturedCannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA
2/12/2024	08:00	EDGAR2	Form 8-K - Current report
2/12/2024	07:30	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
1/08/2024	08:00	EDGAR2	Form 3 - Initial statement of beneficial ownership of..
1/08/2024	07:30	EDGAR2	Form 8-K - Current report
12/20/2023	16:08	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/20/2023	16:08	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/20/2023	16:05	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/15/2023	07:30	EDGAR2	Form 8-K - Current report
11/13/2023	07:30	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/23/2023	16:30	EDGAR2	Form 8-K - Current report
10/16/2023	16:31	EDGAR2	Form 424B3 - Prospectus [Rule 424(b)(3)]
10/11/2023	16:30	EDGAR2	Form 8-K - Current report
10/06/2023	16:30	EDGAR2	Form S-3 - Registration statement under Securities Act of..
9/27/2023	19:46	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
9/26/2023	08:10	EDGAR2	Form 8-K - Current report
9/05/2023	15:54	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/25/2023	17:01	EDGAR2	Form S-8 - Securities to be offered to employees in employee..
8/25/2023	16:21	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
8/25/2023	16:15	EDGAR2	Form DEF 14A - Other definitive proxy statements
8/11/2023	07:31	EDGAR2	Form 8-K - Current report
8/11/2023	07:15	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
7/24/2023	17:30	EDGAR2	Form 8-K - Current report
7/18/2023	16:37	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
7/18/2023	16:36	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
7/18/2023	16:36	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
7/18/2023	16:34	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
7/18/2023	16:32	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
7/18/2023	16:28	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
7/18/2023	16:26	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
7/10/2023	09:00	PRNUS	Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON..
7/07/2023	08:30	EDGAR2	Form 8-K - Current report
7/07/2023	08:00	PRNUS	Acasti Pharma Announces 1-for-6 Reverse Stock Split
7/05/2023	16:00	EDGAR2	Form 8-K - Current report
7/05/2023	09:00	PRNUS	Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase..
6/23/2023	07:00	PRNUS	Acasti Pharma Reports Fiscal Year 2023 Operational Results
6/22/2023	09:00	PRNUS	Acasti Announces Appointment of New Scientific Advisory..
5/17/2023	09:00	PRNUS	Acasti to Participate in the Lytham Partners Spring 2023..
5/08/2023	07:00	PRNUS	Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety..